Roche reports slightly better sales than predicted in Q1

In Q1 2021, pharmaceutical company Roche has had better sales than predicted, especially in terms of diagnostics and hemophilia drug Hemlibra.
Photo: Michael Buholzer/Reuters/Ritzau Scanpix
Photo: Michael Buholzer/Reuters/Ritzau Scanpix
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Swiss pharmaceutical giant Roche has had better sales than the company forecast in the first three months of the year, as diagnostics equipment and the hemophilia medicine Hemlibra in particular have sold surprisingly well, according to the firm's Q1 report.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading